News

Pfizer Oncology Award

The yearly Pfizer Oncology Award is worth € 25.000 and is intended to support, recognise and encourage one innovative project in Belgium or Luxembourg that improves the quality and/or availability of patient care in oncology. The Pfizer Oncology Award is open to any project related to the clinical, surgical and medical or technical aspects of patient care in oncology, but also to different ways of collaboration and/or organisation between various health care providers or between levels of care during the course of the disease.

Pfizer Oncology Award

Read more

FDA Approves Palbociclib in Combination With Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

On February 19, 2016, the U.S. Food and Drug Administration approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

To read the whole article click here

Read more